30,570 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Purchased by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. purchased a new position in Aligos Therapeutics, Inc. (NASDAQ:ALGS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 30,570 shares of the company’s stock, valued at approximately $1,218,000. Avantax Advisory Services Inc. owned approximately 0.85% of Aligos Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. AlphaMark Advisors LLC raised its position in shares of Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after buying an additional 1,000 shares during the last quarter. Drive Wealth Management LLC bought a new stake in Aligos Therapeutics in the 4th quarter valued at $916,000. Golden State Wealth Management LLC bought a new stake in Aligos Therapeutics in the 4th quarter valued at $107,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Aligos Therapeutics by 19.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock worth $569,000 after purchasing an additional 2,306 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Price Performance

Shares of ALGS opened at $10.76 on Wednesday. The business’s 50 day simple moving average is $22.97 and its 200-day simple moving average is $20.46. Aligos Therapeutics, Inc. has a 1 year low of $6.76 and a 1 year high of $46.80. The stock has a market capitalization of $65.79 million, a price-to-earnings ratio of -0.81 and a beta of 2.52.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Monday, March 10th. The company reported ($13.08) EPS for the quarter, missing analysts’ consensus estimates of ($2.63) by ($10.45). The business had revenue of $0.63 million during the quarter, compared to analysts’ expectations of $0.43 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. During the same period in the previous year, the business earned ($5.50) earnings per share. On average, sell-side analysts expect that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their target price on Aligos Therapeutics from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th.

Aligos Therapeutics Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).